{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.2","upperLimit":"31.9","value":"6.7"},{"groupId":"OG002","lowerLimit":"0.1","upperLimit":"24.9","value":"5.0"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"38.3","value":"12.5"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"20.6","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"16"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experienced CR or PR as assessed by investigator is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"V941(mRNA-5671/V941) 1 mg administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles","id":"OG000","title":"Part 1: V941 Monotherapy"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles","id":"OG001","title":"Part 1: V941 + Pembrolizumab"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG002","title":"Part 2: Expansion Cohort 1 Non-small Cell Lung Cancer (V941 + Pembrolizumab)"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG003","title":"Part 2: Expansion Cohort 2 Colorectal Cancer (V941 + Pembrolizumab)"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG004","title":"Part 2: Expansion Cohort 3 Pancreatic Adenocarcinoma (V941 + Pembrolizumab)"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 dose of study treatment. Per protocol, the 1 participant who switched over from Arm 1 Part 1: V941 Monotherapy to Arm 2 Part 1: V941 + Pembrolizumab was excluded from Arm 2 Part 1: V941 + Pembrolizumab for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 24 months","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}